{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:56:29Z","timestamp":1785491789021,"version":"3.56.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82220108014"],"award-info":[{"award-number":["82220108014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010104","name":"Tianjin Medical University","doi-asserted-by":"publisher","award":["22ZYYLCZD02"],"award-info":[{"award-number":["22ZYYLCZD02"]}],"id":[{"id":"10.13039\/501100010104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA1802903"],"award-info":[{"award-number":["2024YFA1802903"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.dsx.2025.103369","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T22:58:30Z","timestamp":1766876310000},"page":"103369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of finerenone in the treatment of primary aldosteronism: A prospective clinical study"],"prefix":"10.1016","volume":"20","author":[{"given":"Shuo","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2025.103369_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.dsx.2025.103369_bib2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1530\/EJE-17-0978","article-title":"Primary aldosteronism: key characteristics at diagnosis: a trend toward milder forms","volume":"178","author":"Heinrich","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.dsx.2025.103369_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1210\/endrev\/bnad024","article-title":"Biomarkers to guide medical therapy in primary aldosteronism","volume":"45","author":"Hundemer","year":"2024","journal-title":"Endocr Rev"},{"key":"10.1016\/j.dsx.2025.103369_bib4","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1161\/HYPERTENSIONAHA.119.14063","article-title":"Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit","volume":"75","author":"Burrello","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.dsx.2025.103369_bib5","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1210\/jc.2008-2116","article-title":"Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's registry","volume":"94","author":"Born-Frontsberg","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.dsx.2025.103369_bib6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2362.2010.02462.x","article-title":"The association of serum potassium level with left ventricular mass in patients with primary aldosteronism","volume":"41","author":"Lin","year":"2011","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.dsx.2025.103369_bib7","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-19-0215","article-title":"Therapy of endocrine disease: medical treatment of primary aldosteronism","volume":"181","author":"Lechner","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.dsx.2025.103369_bib8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2017.03.011","article-title":"True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis","volume":"188","author":"Vukadinovi\u0107","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.dsx.2025.103369_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","article-title":"The evolution of aldosterone antagonists","volume":"217","author":"Garthwaite","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.dsx.2025.103369_bib10","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.dsx.2025.103369_bib11","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor Coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.dsx.2025.103369_bib12","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/13543784.2021.2002844","article-title":"Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics","volume":"30","author":"Barrera-Chimal","year":"2021","journal-title":"Expet Opin Invest Drugs"},{"key":"10.1016\/j.dsx.2025.103369_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11906-022-01177-6","article-title":"The time to reconsider mineralocorticoid receptor blocking strategy: arrival of nonsteroidal mineralocorticoid receptor blockers","volume":"24","author":"Tezuka","year":"2022","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.dsx.2025.103369_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.13566","article-title":"Renal effects and safety between Asian and Non-Asian chronic kidney disease and type 2 diabetes treated with nonsteroidal mineralocorticoid antagonists","volume":"16","author":"Xu","year":"2024","journal-title":"J Diabetes"},{"key":"10.1016\/j.dsx.2025.103369_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102615","article-title":"Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials","volume":"49","author":"Pamporis","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.dsx.2025.103369_bib16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/dom.15327","article-title":"Non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes","volume":"26","author":"Solis-Herrera","year":"2024","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2025.103369_bib17","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/eurheartj\/ehad811","article-title":"Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials","volume":"45","author":"Oraii","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.dsx.2025.103369_bib18","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.dsx.2025.103369_bib19","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1159\/000541441","article-title":"A trial of finerenone in a patient with primary aldosteronism","volume":"49","author":"Karanovi\u0107 \u0160tambuk","year":"2024","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.dsx.2025.103369_bib20","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/jch.14877","article-title":"Primary aldosteronism with postoperative elevation of aldosterone treated effectively by finerenone: a case report","volume":"26","author":"Yu","year":"2024","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.dsx.2025.103369_bib21","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa282","article-title":"Development and validation of criteria for sparing confirmatory tests in diagnosing primary aldosteronism","volume":"105","author":"Wang","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.dsx.2025.103369_bib22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dsx.2025.103369_bib23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/cpt1978244465","article-title":"Gynecomastia induced in normal males by spironolactone","volume":"24","author":"Huffman","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dsx.2025.103369_bib24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ando.2016.01.010","article-title":"SFE\/SFHTA\/AFCE consensus on primary aldosteronism, part 7: medical treatment of primary aldosteronism","volume":"77","author":"Pech\u00e8re-Bertschi","year":"2016","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.dsx.2025.103369_bib25","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.dsx.2025.103369_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11154-022-09729-6","article-title":"Primary aldosteronism in pregnancy","volume":"24","author":"Forestiero","year":"2023","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.dsx.2025.103369_bib27","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jaad.2018.10.023","article-title":"Lack of evidence for feminization of males exposed to spironolactone in utero: a systematic review","volume":"80","author":"Liszewski","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.dsx.2025.103369_bib28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41440-023-01412-w","article-title":"Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism","volume":"47","author":"Yoshida","year":"2024","journal-title":"Hypertens Res"},{"key":"10.1016\/j.dsx.2025.103369_bib29","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dsx.2025.103369_bib30","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dsx.2025.103369_bib31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/HJH.0000000000003330","article-title":"Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes","volume":"41","author":"Agarwal","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.dsx.2025.103369_bib32","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.ekir.2020.06.012","article-title":"Associations between changes in plasma renin activity and aldosterone concentrations and changes in kidney function after treatment for primary aldosteronism","volume":"5","author":"Kobayashi","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.dsx.2025.103369_bib33","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1161\/HYPERTENSIONAHA.119.13131","article-title":"Association between acute fall in estimated glomerular filtration rate after treatment for primary aldosteronism and long-term decline in renal function","volume":"74","author":"Kobayashi","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.dsx.2025.103369_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0000000000002216","article-title":"Renal damage in primary aldosteronism: a systematic review and meta-analysis","volume":"38","author":"Monticone","year":"2020","journal-title":"J Hypertens"},{"key":"10.1016\/j.dsx.2025.103369_bib35","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J Endocrinol"},{"key":"10.1016\/j.dsx.2025.103369_bib36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.dsx.2025.103369_bib37","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","article-title":"Long-term renal outcomes in patients with primary aldosteronism","volume":"295","author":"Sechi","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.dsx.2025.103369_bib38","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1530\/EJE-21-0018","article-title":"Renin, a marker for left ventricular hypertrophy, in primary aldosteronism: a cohort study","volume":"185","author":"K\u00f6hler","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.dsx.2025.103369_bib39","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab174","article-title":"Increased dosage of MRA improves BP and urinary albumin excretion in primary aldosteronism with suppressed plasma renin","volume":"6","author":"Saiki","year":"2022","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.dsx.2025.103369_bib40","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1001\/jamacardio.2018.2003","article-title":"Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism","volume":"3","author":"Hundemer","year":"2018","journal-title":"JAMA Cardiol"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402125001869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402125001869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:50:10Z","timestamp":1773942610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402125001869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1871402125001869"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2025.103369","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of finerenone in the treatment of primary aldosteronism: A prospective clinical study","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2025.103369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103369"}}